May 18, 2016.
Forbes
reports that Valeant Pharmaceuticals is planning to pay CFO Robert L. Rosiello and executives Dr. Ari Kellen and Anne C. Whitaker $1 million retention bonuses, as well as “special equity awards” of $2.8 million, $3.8 million and $1.25 million, respectively, in the form of restricted stock units that vest over 18-months. Antoine Gara writes that these heavy retention bonuses "further indicate pay will be a big part of working for a kinder and gentler Valeant. Or," he adds, "perhaps, Valeant has become such a toxic workplace only heavy incentives can generate loyalty inside the company".
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.